Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HBW-3220 in mature B-cell lymphoma in China
CTR20221130Phase 2Active
- Sponsor
- Hyperway Pharmaceutical
- Start
- May 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HBW-3220 in mature B-cell lymphoma, sponsored by Hyperway Pharmaceutical. Started May 2022; status: active.
02
Drugs
HBW-3220
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20221130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221130.